Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2011 - 2026)

Neurocrine Biosciences has reported Long-Term Deferred Tax for 8 years, with the latest figure at $381.4 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 23.63% year-over-year to $381.4 million; the trailing twelve-month figure through Mar 2026 stood at $381.4 million (down 23.63% YoY), and the FY2025 full-year result was $320.3 million, down 34.05% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $381.4 million, up from $320.3 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $536.8 million in Q2 2025, with the low at $305.9 million in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $387.4 million across 5 years, with a median of $378.2 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 33.95% — and 2025, when it sank 34.05%.
• Neurocrine Biosciences' Long-Term Deferred Tax stood at $305.9 million in 2022, then advanced by 18.54% to $362.6 million in 2023, then jumped by 33.95% to $485.7 million in 2024, then slumped by 34.05% to $320.3 million in 2025, then advanced by 19.08% to $381.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $381.4 million (Q1 2026), $320.3 million (Q4 2025), and $368.5 million (Q3 2025), per Business Quant data.